________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
For patients living with chronic heart failure, time is essential, so start with ENTRESTO (sacubitril/valsartan)1–3
Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring4
ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation5
Improve the chronic HFrEF patient’s experience vs ACEi (enalapril)7,10
ENTRESTO is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
* Local reimbursement criteria apply
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; HFrEF, heart failure with reduced ejection fraction; MoA, mode of action.
References:
- European Heart Journal (2021) 42, 35993726 ESC GUIDELINES doi:10.1093/eurheartj/ehab368
- Maddox TM, et al. J Am Coll Cardiol 2021;77(6):772–810.
- Ponikowski P, et al. ESC Heart Fail 2014;1(1):4–25.
- Mann DL, Bristow MR. Circulation 2005;111(21):2837–2849.
- ENTRESTO Summary of Product Characteristics. Accessed December 2021 at www.medicines.ie
- Claggett B, et al. N Engl J Med 2015;373(23):2289–2290.
- Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
- McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
- Solomon SD, et al. JACC Heart Fail 2016;4(10):816–822.
- Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
- Velazquez EJ, et al. N Engl J Med 2019;380(6):539–548.
- Desai AS, et al. JAMA 2019;322(11):1077–1084.
- Wachter R, et al. Eur J Heart Fail 2019;21(8):998–1007.
- Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.